NKGen Biotech is a leading brand in the field of natural killer (NK) cell therapy. Their mission is to improve patient outcomes in neurodegenerative diseases and cancer by developing safe and effective cellular therapies that harness the power of the patient's immune system. With a focus on innovation, NKGen Biotech is dedicated to the development and commercialization of autologous, allogeneic, and CAR-NK NK cell therapies.

At the core of their groundbreaking technology is the proprietary SNK (super-activated) platform. Spearheading this industry-disrupting technology are their experienced and knowledgeable Senior Leadership, Senior Advisors, and Management Team. With expertise in neurodegeneration and immune-oncology, they are passionate about strengthening the immune system and advancing the field of cellular therapies.

NKGen Biotech's offerings include clinical-stage treatments for both neurodegenerative and oncological diseases. They have a robust pipeline of therapies, and their commitment to scientific excellence is showcased through their scientific publications. Patients and healthcare professionals can find further information, news, and career opportunities on their website.

With corporate headquarters in Santa Ana, CA, and an office in Irvine, CA, NKGen Biotech is poised to transform patient care with their state-of-the-art cellular therapies